膝下浅静脉干微泡沫消融在既往大隐静脉治疗患者中的安全性和有效性
本研究回顾性分析了68条肢体(49例患者),这些患者既往接受过大隐静脉消融或剥脱,因症状性膝下静脉干反流接受聚多卡醇微泡沫消融。中位随访97天,闭合率96%,症状缓解率78%,术后VCSS中位数从12.5降至10(P<.001),血栓不良事件少。
要点
- 膝下静脉干微泡沫消融在既往大隐静脉治疗患者中闭合率达96%,症状缓解率78%。
- 术后VCSS中位数从12.5降至10(P<.001),绝对溃疡愈合率64%。
- 血栓延伸事件少,1例腘静脉血栓经抗凝消退,无肺栓塞或神经损伤。
核心结论
- 膝下静脉干微泡沫消融对既往接受过大隐静脉介入的严重难治性慢性静脉功能不全患者安全有效,闭合率优异且症状缓解明显,血栓不良事件少。
研究设计与样本
- 回顾性分析前瞻性维护数据库,纳入2018年4月至2021年4月间因症状性膝下静脉干反流接受聚多卡醇微泡沫消融且既往行大隐静脉消融或剥脱的患者,最终68条肢体(49例患者)符合标准。
主要发现
- 中位随访97天(范围33-457天),闭合率96%,总体症状缓解率78%。
- 术后VCSS中位数从12.5降至10(P<.001),绝对溃疡愈合率64%(25个溃疡中16个愈合)。
- 1例患者出现腘静脉血栓延伸,经抗凝治疗消退;1例无症状患者小隐静脉消融后出现腓肠肌静脉非闭塞性血栓,未抗凝。
- 术后疼痛、静脉炎和肿胀分别报告于12%、12%和2%的患者,均在末次随访时消退。
- 3条肢体在初始闭合后研究期间出现静脉干再通,均在使用慢性口服抗凝药。
关键数值与推荐
- 63%患者术前CEAP分级为C4-C6。
- 治疗静脉包括膝下大隐静脉(n=45)和小隐静脉(n=23)。
临床怎么用
- 对于既往接受过大隐静脉消融或剥脱、存在症状性膝下静脉干反流的患者,可考虑使用商用聚多卡醇微泡沫进行化学消融。
- 术后需关注血栓事件,尽管发生率低,但可能发生腘静脉或腓肠肌静脉血栓。
局限性
- 回顾性研究设计,样本量较小(68条肢体),随访时间中位数较短(97天)。
- 排除了未按 protocol 完成术后48-72小时 duplex 超声随访的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients requiring thermal or chemical ablation of below knee (BK) truncal veins often have their proximal saphenous veins treated initially and comprise a study population with multilevel, refractory chronic venous insufficiency. The study objective was to assess the outcomes after microfoam ablation of BK truncal and tributary veins in patients with a history of proximal great saphenous vein (GSV) ablation or stripping. METHODS: A retrospective review of a prospectively maintained database was performed. All the patients who had undergone endovenous chemical ablation with commercially manufactured polidocanol microfoam for symptomatic BK truncal vein reflux after a previous saphenous ablation or stripping were identified. The patients had undergone duplex ultrasound scanning 48 to 72 hours after the procedure; those who had not adhered to the recommended follow-up protocol were excluded. The demographic data, CEAP (clinical, etiologic, anatomic, pathophysiologic) classification, venous clinical severity score (VCSS), procedure details, adverse thrombotic events, and follow-up data were abstracted. RESULTS: Between April 2018 and April 2021, 201 limbs were treated for symptomatic superficial truncal vein reflux with microfoam ablation. Of the 201 limbs, 68 in 49 patients met the inclusion criteria for the present study. The veins treated included the BK GSV (n = 45) and small saphenous vein (n = 23). The median follow-up was 97 days (range, 33-457 days) for the entire cohort. Most patients (63%) had a preoperative CEAP classification of C4 to C6. The median preoperative VCSS was 12.5. All the limbs that had undergone microfoam ablation in this cohort had a previously treated proximal ipsilateral GSV, with either thermal ablation or stripping. The median postoperative VCSS after BK treatment decreased to 10 (P < .001). The closure rate at the last follow-up was 96%. The overall symptomatic relief was 78% at the last follow-up. The absolute ulcer healing rate during the study period was 64% (16 of 25 ulcers had healed). One patient had developed thrombus extension into the popliteal vein, which resolved with anticoagulation therapy. One asymptomatic patient had developed nonocclusive thrombus in a gastrocnemius vein after small saphenous vein ablation. Because she was asymptomatic, anticoagulation therapy was not prescribed. Postoperative pain, phlebitis, and swelling were reported in 12%, 12%, and 2% of patients, respectively, and all had resolved at the last follow-up visit. Three limbs treated with chronic oral anticoagulant agents had had recanalized truncal veins during the study period after initial closure. No pulmonary emboli or neurologic adverse events were reported. No symptoms of saphenous or sural nerve injury had occurred. CONCLUSIONS: Endovenous chemical ablation with commercially manufactured polidocanol microfoam of BK truncal veins is a safe and effective treatment for patients with severe, refractory chronic venous insufficiency and prior saphenous interventions. This technique results in excellent overall closure rates and symptomatic relief with low adverse venous thrombotic events, across a wide range of CEAP classes.
引用
- Jimenez JC, Lawrence PF, Pavlyha M, et al. Endovenous microfoam ablation of below knee superficial truncal veins is safe and effective in patients with prior saphenous treatment across a wide range of CEAP classes. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34474174. doi:10.1016/j.jvsv.2021.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。